DOBI MEDICAL SYSTEMS SHOWCASES NEW BREAST CANCER DIAGNOSTIC IMAGING SYSTEM
MAHWAH, NJ, December 8, 2000. DOBI Medical Systems, LLC announced its recent participation at the Radiological Society of North America's (RSNA) 86th Scientific Assembly and Annual Meeting November 26 December 1, 2000 held in Chicago's McCormick Center.
DOBI Medical showcased its newly designed Dynamic Optical Breast Imaging System (DOBI�) created for the early and accurate detection of breast cancer. The system works by identifying vascular changes in the breast associated with malignancy. Angiogenesis, or the growth of new blood vessels to support malignant tumor growth, is becoming more widely recognized by the medical and scientific communities as a critical aspect of cancer growth in the human body. DOBI Medical's new technology is unique in that it is designed to image angiogenesis based vascular changes associated with malignancy, rather than identifying actual tumors or calcifications as is the case today in diagnosing breast cancer. By concentrating on identifying angiogenesis developments in the breast, it is thought that earlier and more accurate detection of breast cancer will be possible.
The DOBI System is an innovative breast cancer diagnostic system, initially being tested as a secondary screening device, to non-invasively differentiate benign from malignant lesions. A key purpose of the DOBI system is to substantially reduce the large number of invasive surgical breast biopsies performed that turn out to be benign while maintaining a high sensitivity to true malignancies. These surgical biopsy procedures, which often produce benign results, are estimated to cost over $5 billion annually worldwide. The DOBI System provides a digital, non-invasive, pain free test that takes less than 10 minutes to complete. A series of patents and trademark approvals protect the DOBI System's unique position in the marketplace.
The DOBI System is designated an investigational device at this time and may be used only for research purposes in the U.S. pending FDA approval. Use abroad is also subject to the regulations of the respective country. Except for historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties.
The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In addition to the factors set forth above, other important factors that could cause actual results to differ materially include, but are not limited to, technical risks associated with new technology development, government regulatory approval, market acceptance of our product, competition and technological change.
For further information:
DOBI Medical International